News

In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.

David Hong, MD, explains why larotrectinib may be chosen over other TRK inhibitors for the treatment of NTRK fusion-positive lung cancer.

Valencia D. Thomas, MD, MHCM, discusses the unmet needs which remain in the non-melanoma skin cancer space.

The FDA has approved durvalumab for the treatment of patients with locally advanced or metastatic biliary tract cancer.

Treatment with AST-301 will be explored in patients with HER2-low breast cancer in the phase 2 Cornerstone-011 study.

Florida Cancer Specialists & Research Institute welcomes Board-certified hematologist/oncologist Shivtaj Mann, DO to the statewide practice. He is providing care to patients at the FCS Fort Myers Cancer Center, 8260 Gladiolus Drive, Fort Myers, FL 33908.

Florida Cancer Specialists & Research Institute, LLC held a ribbon-cutting ceremony on August 18, 2022 to celebrate the opening of its newest clinical site in Pasco County.

Sumanta K. Pal, MD, discusses the safety and efficacy results of the COSMIC-021 clinical trial.

Enrollment has begun for a phase 2 study of a polarized dendritic cell vaccine plus interferon alpha-2b, rintatolimod, and celecoxib in melanoma with PD1/PD-L1-resistance.

The PARP inhibitor rucaparib was shown to improve progression-free survival in a cohort of the ATLANTIS study platform for metastatic urothelial carcinoma.

The use of immune checkpoint inhibitors in anaplastic thyroid cancer shows a similar toxicity profile to that seen in PD-1 and PD-L1 targeting therapies.

The targeted alpha therapy, FPI-1966, has been dosed for the first time in a phase 1/2 study of patients with advanced solid tumors that express FGFR3.

Data from the phase 2 CADENZA trial revealed front-line pivekimab sunirine to demonstrate clinical activity in patients with blastic plasmacytoid dendritic cell neoplasm.

Here is a look back at the FDA happenings from the month of August 2022.

The CoMMpass genomic data set of patients with multiple myeloma was utilized by investigators, contributing to 19 abstracts reported at the International Myeloma Society.

In the CodeBreaK 200 clinical trial, progression-free survival was extended with sotorasib treatment in patients with KRAS G12C-mutated non–small cell lung cancer vs standard of care chemotherapy.

Top-line data from the SELECT trial of vopratelimab plus pimivalimab vs pimivalimab alone missed its primary end point of mean tumor change but showed encouraging trends for secondary end points.

In an interview with Targeted Oncology following the tweet chat, Warren Swegal, MD, discussed the key takeaways from the discussion, including his thoughts on the case and what he hopes will be addressed in the future of the thyroid cancer space.

Karen L. Reckamp, MD, discusses the key findings of the phase 2 Lung-MAP substudy S1800A for patients with stage IV, previously-treated non–small cell lung cancer.

In an interview with Targeted Oncology, Chen Yuan, MD, further discussed the research on the age-dependent associations and risks for patients with pancreatic cancer.

The FDA has cleared TakeAim Leukemia study to continue enrolling emavusertib with or without azacytidine and venetoclax in patients with acute myeloid leukemia or myelodysplastic syndrome.

Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.

The phase 3 MAGNOLIA study has begun enrolling patients to examine abelacimab for the treatment of thrombosis associated with cancer.

William J. Gradishar, MD, discusses the most recent evolutions in the management of patients with advanced breast cancer.

To assist clinicians in identifying, monitoring, and managing immune-related adverse effects, the American Society of Clinical Oncology issued guidelines in June 2022 updated by a multidisciplinary panel.

An investigational new drug application has been accepted by the FDA allowing for the start of a phase 1 trial to evaluate the tolerability of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies

Hot flashes related to adjuvant hormone therapy were predictive of worse breast cancer outcomes, according to research on disease-free survival and treatment discontinuation in patients with and without hot flashes.

Two genes to assist in determining primary resistance to immunotherapy for patients with mismatch repair–deficient/microsatellite instability–high gastrointestinal cancers have been identified.

Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.

Nazli Dizman, MD, internal medicine resident at Yale Department of Internal Medicine, discusses the role of the gut microbiome in cancers like renal cell carcinoma.